58 results about "Encephalitis Viruses" patented technology

This invention involves, among other things, elements that stimulate an immune response. Which includes: a) one or more antigens of Avibacterium paragallinarum and One or more antigens of avian brain and spinal cord rhizomatous virus and one antigen. or more of avian porcine ... Furthermore, this invention relates to a method for immunizing animals which includes administration. The animal drug contains components that stimulate the immune response of this invention; moreover, This invention relates to a method of treating or preventing clinical signs caused by Avibactericum. Paragallinarum, a viral infection that causes encephalitis and spinal cord inflammation in birds and avian pox virus in animals. Essential, a method that involves administering medication to animals in effective dosages as a form of treatment. The components that stimulate an immune response are consistent with this invention;

The invention belongs to the technical field of virus detection, and particularly relates to a primer probe composition for detecting Japanese encephalitis virus and application, the primer probe composition comprises a probe, an upstream primer and a downstream primer, the nucleotide sequence of the upstream primer is shown as SEQ ID No.3, and the nucleotide sequence of the downstream primer is shown as SEQ ID No.6. According to the primer probe composition, the invention provides a non-diagnostic method for detecting the Japanese encephalitis virus, and the method has the advantages of rapidness, real time, strong specificity, high sensitivity, simplicity and convenience in operation and suitability for various fluorescence detection equipment, and can accurately detect the Japanese encephalitis virus from a sample to be detected.

The present disclosure is concerned with substituted tetrahydrobenzothiophene and tetrahydropyridothiophene compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds in the treatment of viral infections due to a Flavi virus (e.g, yellow fever, Japanese encephalitis, dengue (DENV), West Nile virus (WNV), zika (ZIKV), tick-bome encephalitis virus. Kunjin virus. Murray Valley encephalitis, St Louis encephalitis, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Hepatitis C virus) or an Alphavirus (e.g., Venezeulan equine encephalitis virus, chikungunya virus (CHIKV), Ross River virus, Mayaro virus, Sindbis virus). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

This invention relates to the field of pharmaceutical technology, specifically the application of NEDD8 activator in the preparation of drugs for treating Japanese encephalitis. Using human neuroblastoma cells (SH-SY5Y) as target cells, this invention utilizes activators from a library of ubiquitinated compounds to target and activate key enzymes in the ubiquitination pathway, aiming to identify host factors associated with Japanese encephalitis virus (JEV) infection of SH-SY5Y cells. This helps to understand the mechanism by which JEV invades the central nervous system and causes neuronal cell damage, and also provides new targets for therapeutic drugs against JEV-induced Japanese encephalitis. This invention experimentally discovered that NEDD8 activator (NAE) has the property of inhibiting JEV infection of SH-SY5Y cells. This invention provides the application of NEDD8 activator in the preparation of drugs for treating Japanese encephalitis, offering new targets and treatment strategies for the prevention and treatment of JEV.

The present application relates to the field of biological medicine, in particular to a kind of muscone in the application of viral inhibitor.The viral inhibitor of the present application is used to inhibit the replication of Japanese encephalitis virus and / or porcine epidemic diarrhea virus.The present application finds that muscone has no cytotoxicity, and does not directly inactivate virus, but produces antiviral effect on Japanese encephalitis virus by inhibiting NLRP3 / Caspase-1, Caspase-9 / Caspase-3 / Bax / BCL-2, JNK / ERK / P38 and other signal pathways, and inhibits porcine epidemic diarrhea virus invasion into cells by reducing caveolin level.The antiviral effect is remarkable, the mechanism of action is clear, the selectivity is high, and the safety is better.

This invention relates to the field of pharmaceutical technology, specifically the application of NEDD8 activator enzyme inhibitors or their hydrochlorides in the preparation of drugs for treating Japanese encephalitis. This invention utilizes inhibitors from a library of ubiquitinated compounds to target and inhibit key enzymes in the ubiquitination pathway, aiming to identify host factors associated with Japanese encephalitis virus (JEV) infection of SH-SY5Y cells. This contributes to understanding the mechanism by which JEV invades the central nervous system and causes neuronal cell damage, and also provides new targets for therapeutic drugs against JEV-induced Japanese encephalitis. This invention discovers that NEDD8 activator enzyme (NAE) inhibitors or their hydrochlorides possess the property of inhibiting JEV infection of SH-SY5Y cells. This invention provides the application of NEDD8 activator enzyme inhibitors or their hydrochlorides in the preparation of drugs for treating Japanese encephalitis, offering new targets and therapeutic strategies for the prevention and treatment of JEV.

The invention relates to the technical field of vaccine preparation, in particular to a porcine Japanese encephalitis virus and porcine parvovirus VP2 protein bivalent vaccine as well as a preparation method and application thereof. According to the invention, the JEV-PPV VP2 combined vaccine is prepared by combining the JEV whole-virus inactivated vaccine with the VLP assembled by the expressed PPV VP2 protein, so that the organism can be induced to generate good cellular immunity and humoral immunity, the organism is protected from being damaged by PPV and JEV, and a certain basis and direction are provided for research on the aspect of combined use of vaccines in the future.

The present invention relates to a multiplex gene detection system for viral and bacterial infection of the central nervous system, comprising forward and reverse primers for detecting enterovirus, human double echovirus, Mycobacterium tuberculosis, Listeria monocytogenes, Streptococcus pneumoniae, varicella zoster virus, mumps virus, cytomegalovirus, herpes simplex virus type 1, herpes simplex virus type 2, Neisseria meningitidis, Epstein-Barr virus, Streptococcus agalactiae, Haemophilus influenzae, human herpes virus type 6, Escherichia coli K1 and Japanese encephalitis virus, and the detection sample is cerebrospinal fluid. The multiplex gene detection product for viral and bacterial infection of the central nervous system of the present invention has high throughput, low cost, high sensitivity and good specificity, and is used for synchronous identification and semi-quantitative analysis of multiple viral and bacterial infections of the central nervous system.

The invention provides a brain organoid / encephalitis B virus infected brain organoid model and a construction method and application thereof, and belongs to the technical field of organoid. The invention provides the kit for constructing the brain organoid, the brain organoid is constructed on the basis of the kit, the construction method of the brain organoid is provided, and the constructed brain organoid model shows clear staged development characteristics, completely reproduces cell diversity in the human brain development process and forms ventricular-like structural characteristics. The encephalitis B virus infected brain organ model constructed on the basis of the obtained brain organs can be used for deeply analyzing the pathogenic process and related immune response characteristics of JEV infected human brain, researching and developing vaccines related to encephalitis B virus and screening antiviral drugs.

The present invention discloses the application of siRNA targeting the mGluR2 gene, monoclonal antibodies against the extracellular domain of the protein encoded by the mGluR2 gene, truncated peptides containing the extracellular domain of the protein encoded by the mGluR2 gene, or recombinant vectors containing the gRNA gene sequence targeting the mGluR2 gene and the CAS9 protein gene sequence in the preparation of preparations for inhibiting influenza virus, swine acute diarrhea syndrome coronavirus, porcine epidemic diarrhea virus, Japanese encephalitis virus, and porcine reproductive and respiratory syndrome virus. The present invention also discloses the application of a genetic engineering operation method for knocking out the mGluR2 gene in the preparation of a new mouse strain with enhanced influenza resistance. The aforementioned applications have prospects for promotion.

The application discloses a recombinant getah virus expressing E protein of Japanese encephalitis virus, the virus has the E protein gene of the Japanese encephalitis virus, and the E protein gene is located between Cap and E3 genes of the genome of the getah virus. A corresponding construction method is also established, the getah virus is used as a parent strain, an infectious clone pGETV-GV thereof is used as a carrier, a truncated E protein of the Japanese encephalitis virus is inserted between Cap and E3 by using a genetic engineering method, and the recombinant getah virus rGECJEV-E is obtained. Tests show that the recombinant getah virus rGECJEV-E has the characteristics of good performance, good stability and high expression amount of exogenous protein, the expressed protein has good immunogenicity, can provide immunoprotection for the attack of the Japanese encephalitis virus, and the safety of the recombinant strain is relatively high. Therefore, the recombinant virus has great potential in preparation of a vaccine or a medicine for preventing or treating the getah virus and / or the Japanese encephalitis virus, and is expected to develop a recombinant bivalent vaccine for the getah virus and the Japanese encephalitis.

The invention relates to the field of biological medicine, in particular to application of muscone in preparation of a virus inhibitor. The virus inhibitor is used for inhibiting replication of Japanese encephalitis virus and / or porcine epidemic diarrhea virus. It is found that muscone has no cytotoxicity, does not directly inactivate viruses, generates an antiviral effect on Japanese encephalitis viruses by inhibiting signal channels such as NLRP3 / Caspase-1, Caspase-9 / Caspase-3 / Bax / BCL-2, JNK / ERK / P38 and the like, and inhibits porcine epidemic diarrhea viruses from invading cells by reducing the level of litter protein. The antiviral effect is obvious, the action mechanism is clear, the selectivity is high, and the safety is better.

The invention discloses application of isoquinoline alkaloid YS-49 in preparation of a medicine for treating epidemic encephalitis B virus infection, and belongs to the technical field of medical application. When the concentration of the isoquinoline alkaloid YS-49 is 18 [mu] g / mL, the epidemic encephalitis B virus almost loses activity, the isoquinoline alkaloid YS-49 has a good treatment effect on the epidemic encephalitis B virus, and a new application direction is provided for the isoquinoline alkaloid YS-49.

The invention belongs to the technical field of virus detection, and particularly relates to a dual-channel real-time fluorescent quantitative PCR (polymerase chain reaction) detection primer, a probe, a detection kit, a detection method and an application of the dual-channel real-time fluorescent quantitative PCR detection primer. Comprising specific primers of the Intity cereal encephalitis virus (Australian encephalitis virus) as shown in SEQ ID NO.1-2 and a probe of the Intity cereal encephalitis virus as shown in SEQ ID NO.3. The detection sensitivity is high, and the lowest detection limit can reach 8 copies / mL; the detection time period is short, nucleic acid detection can be completed within 40 minutes, and the kit is suitable for clinical and bedside rapid detection and diagnosis; the detection specificity is high, and cross amplification with other 80 pathogens is avoided; the detection accuracy is 100%; virus quantitative analysis can be carried out, and the quantitative linear range is good; the detection repeatability is good, and the precision is high.

The present invention discloses a monoclonal antibody against Japanese encephalitis virus and Zika virus and its application, which relates to the technical fields of immunology and molecular virology. The monoclonal antibody or its antigen-binding fragment comprises VH CDR1, VH CDR2 and VH CDR3 with amino acid sequences shown in SEQ ID NO: 1-3, and VL CDR1, VL CDR2 and VL CDR3 with amino acid sequences shown in SEQ ID NO: 4-6. After a large number of experimental studies, the present invention discovers a monoclonal antibody which can specifically recognize and target the extracellular region of the E protein of Japanese encephalitis virus and Zika virus, and can block the binding of the E protein to the cell surface receptor, showing a high ability to neutralize the virus. Therefore, the antibody of the present invention is particularly suitable for diagnosing, preventing and / or treating diseases related to Japanese encephalitis virus and Zika virus infection.

The disclosure provides a Japanese encephalitis virus transmission risk estimation method and device and electronic equipment, relating to the technical field of disease transmission, the method comprises the steps of: determining a first infection force model, a second infection force model, a first incidence overflow rate model and a second incidence overflow rate model based on mosquito vector data, host infection kinetics data and host data corresponding to a first time interval; estimating the contribution coefficient of vertical transmission basic infection force and mosquito ovitraps index to the infection force of mosquito vector transmission to the host based on the first infection force model and the second infection force model; estimating the intensity coefficient based on the first incidence overflow rate model and the second incidence overflow rate model; estimating the host data of the second time interval based on the vertical transmission basic infection force, the contribution coefficient of the mosquito ovitraps index to the infection force and the intensity coefficient; in this way, the whole chain quantitative evaluation from mosquito vector to host and from host to host can be realized, and the risk evaluation accuracy of host infection virus in a real scene is improved.

The invention relates to the technical field of nucleic acid molecule detection, and particularly discloses a kit for detecting forest encephalitis virus nucleic acid through an RT-MIRA / Cas12a one-step method and application thereof.According to the method, total RNA extracted from ticks or infected blood samples serves as a template, target sequence amplification is conducted through the RT-MIRA / Cas12a rapid amplification technology, then the target sequence is assembled with Cas12a protein and crRNA to form a compound, and the target sequence is detected through an RT-MIRA / Cas12a one-step method. And activating the excision activity of Cas12a, and cutting the free single-stranded DNA probe in the system. According to the detection result, visual fluorescence can be observed through naked eyes under an ultraviolet light source or a blue light source, or generation of a red strip at the position of a detection line is observed through a CRISPR single system detection test strip. The method has good specificity on the forest encephalitis virus, and has no cross reaction with other tick-borne viruses, parasites and common bacteria; the kit has the advantages of simplicity and convenience in operation, rapidness in detection, intuitive result, high sensitivity and the like, and an efficient tool is provided for on-site rapid screening and epidemiological monitoring of the forest encephalitis virus.

The invention discloses a detection system for visually detecting a swine Japanese encephalitis virus based on an RT-RAA-CRISPR / Cas12a system, and the visual detection of the JEV is realized by designing crRNA and RAA amplification primers for a JEV NS1 gene conserved region and triggering the breakage of a double-labeled ssDNA reporter molecule by using the specific recognition and trans-cleavage activity of Cas12a protein to an RAA amplification product. The lower detection limit of the method is 2.04 * 10 < 0 > copies / [mu] L; the clinical sample detection rate is 61.0% and is equivalent to that of 63.4% of PCR (Polymerase Chain Reaction). Therefore, the invention establishes a nucleic acid diagnosis method with strong specificity, high sensitivity, short detection time and simple operation, and the method is also suitable for pig farm on-site epidemic situation screening, animal quarantine ports, grassroots veterinary stations, remote area public health monitoring and other aspects.

The invention discloses a monoclonal antibody of Japanese encephalitis virus and Zika virus and application of the monoclonal antibody, and belongs to the technical field of immunology and molecular virology. The monoclonal antibody or the antigen binding fragment thereof comprises VH CDR1, VH CDR2 and VH CDR3 of which the amino acid sequences are shown as SEQ ID NO: 1-3, and VL CDR1 and VL CDR3 of which the amino acid sequences are shown as SEQ ID NO: 4 and SEQ ID NO: 5, and the amino acid sequence is VL CDR2 of AAS. The monoclonal antibody LZY2086 provided by the invention can be combined with E protein extracellular regions of the encephalitis B virus and the Zika virus with high affinity, and has very strong neutralizing activity on the encephalitis B virus and the Zika virus. Therefore, as a broad-spectrum neutralizing antibody, the monoclonal antibody LZY2086 disclosed by the invention has ideal clinical application value in prevention and treatment of Japanese encephalitis virus and Zika virus infection.

The application discloses application of a host PRKCSH gene as a target point in prevention and treatment of various RNA virus infections. Experiments prove that knocking out the PRKCSH gene of a pig can significantly inhibit adhesion and invasion of Japanese B encephalitis virus to a host cell, and can also significantly inhibit replication of a classical swine fever virus, a porcine transmissible gastroenteritis virus, a Senecavirus, a porcine epidemic diarrhea virus and a porcine reproductive and respiratory syndrome virus in the host cell. In addition, knocking out the PRKCSH gene of a human can significantly inhibit replication of the Japanese B encephalitis virus in the host cell. Therefore, specific targeted editing of the PRKCSH gene or interference with protein expression of the PRKCSH gene can inhibit infection of various RNA viruses to host cells.

The invention relates to compounds that are inhibitors of Flavivirus NS2B-NS3 proteases and inhibit replication of flavivirus in cells. Compounds of this invention are useful alone or in combination with other agents for use in the treatment of infections caused by Flaviviruses, in particular by Dengue, West Nile, Zika, Japan Encephalitis viruses.

The invention discloses a process method for producing an attenuated porcine encephalitis B virus by optimizing BHK-21 cells. The process method comprises a shake flask preparation process and a reactor preparation process, the shake flask preparation process is used for virus recovery; the reactor preparation process is used for virus amplification. Optimizing the technological process of preparing the suspension virus by shaking a flask, and optimizing parameters in the aspects of MOI value, cell density and freeze-thaw times after harvesting time; 2, optimizing the technological process of preparing the antigen by shaking a flask, and optimizing parameters in the aspects of MOI value, cell density, harvesting time and preservation conditions; and 3, optimizing the technological process of preparing the antigen by a reactor, wherein parameters in two aspects of pH and temperature are optimized. Compared with the prior art, the preparation method has the advantages that the porcine encephalitis B virus vaccine product can be efficiently and stably produced on an industrial scale through the optimization; powerful technical support is provided for production of porcine encephalitis B vaccines and diagnostic reagents, and the technical progress and industrial development in the field of porcine encephalitis B prevention and control are expected to be promoted.

The invention provides application of a sarcodia montagneana extract in preparation of a composition for inhibiting Japanese encephalitis virus. Wherein the sarcodia montagneana extract is extracted from a sarcodia montagneana frond material or a sarcodia montagneana frond, the sarcodia montagneana extract contains a component for inhibiting the Japanese encephalitis virus, the sarcodia montagneana extract can be applied to resisting infection of the Japanese encephalitis virus and inhibiting the activity of the Japanese encephalitis virus, and the sarcodia montagneana extract does not have cytotoxicity.

The invention discloses application of KML29 in preparation of a medicine for inhibiting Japanese encephalitis virus infection, discovers that KML29 can significantly inhibit Japanese encephalitis virus replication, and discovers that KML29 not only inhibits transcription of Japanese encephalitis virus, but also can reduce expression of NS5 protein. Therefore, the KML29 can be used for preventing or treating the Japanese encephalitis virus.

The application provides a recombinant protein and a construction method and application in tick-borne encephalitis virus vaccine thereof, and the amino acid sequence of the recombinant protein is shown as SEQ ID NO. 2. A novel tick-borne encephalitis virus nano vaccine EDIII-Fd-F nanoparticle is prepared by using a phage-derived Foldon scaffold protein to assist the third domain (TBEV-EDIII) peptide segment of a tick-borne encephalitis virus envelope protein to form a trimer form, and then displaying on the surface of a recombinant human heavy chain ferritin cage structure. The nano particle can protect mice from lethal dose infection of different subtypes of tick-borne encephalitis virus, is simple to prepare, does not involve live virus culture, is safe, has high product yield, and is suitable for large-scale production.

The application provides a hybridoma cell strain, the preservation number of the hybridoma cell strain is CCTCC NO: C2024394, and the hybridoma cell strain is prepared from spleen lymphocytes of mice immunized by a vaccine containing a recombinant protein with an amino acid sequence as shown in SEQ ID NO. 1. Further, the hybridoma cell is used to prepare a monoclonal antibody V6-M15 which can be highly specific to bind to a trimer conformation in a membrane fusion process of EDIII, and the monoclonal antibody V6-M15 can effectively inhibit the amplification of three TBEV, and can provide broad-spectrum protection against three TBEV subtype strains. The application provides a new strategy for developing more effective TBEV specific monoclonal antibodies and prevention and treatment of TBEV.

The invention generally relates to the development of immunogenic compositions comprising a DNA copy of at least one live attenuated plus-sense single-stranded RNA virus genome, such as the genome of a live-attenuated Zika vims (ZIKV), Japanese encephalitis virus (JEV) or yellow fever vims (YFV). The immunogenic compositions can be used for treating or conferring protective immunity against diseases related to plus-sense single-stranded RNA viruses, e.g. for affording prolonged immunoprotection against such viruses and protective immunity is conferred at low diseases, e.g., as low as 300 or 500 ng after administration of a single pLAV dosage.

The invention belongs to the field of development of antiviral drugs, and particularly relates to application of LEI-401 in preparation of drugs for resisting epidemic encephalitis B virus infection. The CAS number of the LEI-401 is 2393840-15-6, the invention discloses that the LEI-401 can obviously inhibit Japanese encephalitis virus replication and reduce virus load for the first time, and proves that the LEI-401 can improve the survival rate of infected mice, has good antiviral activity and safety in an animal model, and can be used for developing drugs for treating or preventing epidemic Japanese encephalitis virus infection. The invention also provides a suspension for resisting epidemic encephalitis B virus infection. The suspension has the advantages of safety, high efficiency and wide application prospect.

The application provides application of embelin in preparation of a medicine for resisting St. Louis encephalitis virus infection. The application has the beneficial effect that the embelin has significant inhibitory effect on NS2B-NS3 protease activity in the St. Louis encephalitis virus, can be used as an inhibitor of the NS2B-NS3 protease in the St. Louis encephalitis virus, and is expected to become a potential medicine for resisting St. Louis encephalitis virus infection.

This invention discloses labeled antibodies and related biological materials, and their application in the detection of tick-borne encephalitis virus (TEV). The application includes any of the following: (1) preparing products for detecting TEV; (2) preparing products binding to the TEV E protein; (3) detecting TEV; and (4) binding to the TEV E protein. Compared with traditional HRP-labeled antibodies, this labeled antibody has higher detection sensitivity.